131 results match your criteria pib-pet assessed

Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.

Brain 2021 Jun 11. Epub 2021 Jun 11.

Department of Radiology, Mayo Clinic, Rochester, Minnesota.

Dementia with Lewy bodies (DLB) is neuropathologically defined by the presence of α-synuclein aggregates, but many DLB cases show concurrent Alzheimer's disease (AD) pathology in the form of β-amyloid plaques and tau neurofibrillary tangles. The first objective of this study was to investigate the effect of AD co-pathology on functional network changes within the default mode network (DMN) in DLB. Secondly, we studied how the distribution of tau pathology measured with PET relates to functional connectivity in DLB. Read More

View Article and Full-Text PDF

C-PIB and I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention.

J Nucl Med 2021 Jun 4. Epub 2021 Jun 4.

Uppsala University, Sweden.

Positron emission tomography (PET) imaging of amyloid-β (Aβ) has become an important component of Alzheimer's disease (AD) diagnosis. C-Pittsburgh compound B (C-PiB) and analogs bind to fibrillar Aβ. However, levels of nonfibrillar, soluble aggregates of Aβ, appear more dynamic during disease progression and more affected by Aβ reducing treatments. Read More

View Article and Full-Text PDF

Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females.

Neurobiol Aging 2021 Apr 22;105:86-98. Epub 2021 Apr 22.

Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.

We assessed sex differences in amyloid- and tau-PET retention in 119 amyloid positive patients with mild cognitive impairment or Alzheimer's disease (AD) dementia. Patients underwent 3T-MRI, C-PIB amyloid-PET and F-Flortaucipir tau-PET. Linear ordinary least squares regression models tested sex differences in Flortaucipir-PET SUVR in a summary temporal region of interest as well as global PIB-PET. Read More

View Article and Full-Text PDF

Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients.

J Alzheimers Dis 2021 May 4. Epub 2021 May 4.

Division of Clinical Geriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Background: The effect of regional brain amyloid-β (Aβ) pathology on specific cognitive functions is incompletely known.

Objective: The relationship between Aβ and cognitive functions was investigated in this cross-sectional multicenter study of memory clinic patients.

Methods: The participants were patients diagnosed with Alzheimer's disease (AD, n = 83), mild cognitive impairment (MCI, n = 60), and healthy controls (HC, n = 32), who had been scanned by 11C-PiB PET in 13 brain regions of both hemispheres and who had been assessed by cognitive tests covering seven domains. Read More

View Article and Full-Text PDF

Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.

Neurology 2021 May 5. Epub 2021 May 5.

Department of Radiology, Massachusetts General Hospital, Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA 02114, USA.

Objective: To compare how structural MRI, Fluorodeoxyglucose (FDG), and Flortaucipir (FTP) PET signal predict cognitive decline in high-amyloid versus low-amyloid participants with the goal of determining which biomarker combination would result in the highest increase of statistical power for prevention trials.

Methods: In this prospective cohort study, we analyzed data from clinically-normal adults from the Harvard Aging Brain Study with MRI, FDG, FTP, and PiB-PET acquired within a year, and prospective cognitive evaluations over a mean three-year follow-up. We focused analyses on pre-defined regions-of-interest: inferior temporal, isthmus cingulate, hippocampus, and entorhinal cortex. Read More

View Article and Full-Text PDF

In vivo detection of beta-amyloid at the nasal cavity and other skull-base sites: a retrospective evaluation of ADNI1/GO.

Ann Nucl Med 2021 Jun 12;35(6):728-734. Epub 2021 Apr 12.

Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada.

Introduction: Amyloid beta (Aβ) is partially cleared from the CSF via skull base perivascular and perineural lymphatic pathways, particularly at the nasal cavity. In vivo differences in Aβ level at the nasal cavity between patients with Alzheimer's disease (AD), subjects with mild cognitive impairment (MCI) and cognitively normal (CN) individuals have not been previously assessed.

Methods: This is a retrospective evaluation of subject level data from the ADNI-1/GO database. Read More

View Article and Full-Text PDF

Improving contrast between gray and white matter of Logan graphical analysis' parametric images in positron emission tomography through least-squares cubic regression and principal component analysis.

Biomed Phys Eng Express 2021 Mar 4. Epub 2021 Mar 4.

Department of Electrical Engineering and Electronics, Graduate School of Engineering, Kogakuin University, 1-24-2 Nishi-shinjuku, Shinjuku-ku, Tokyo, 163-8677, JAPAN.

Logan graphical analysis (LGA) is a method for in vivo quantification of tracer kinetics in positron emission tomography (PET). The shortcoming of LGA is the presence of a negative bias in the estimated parameters for noisy data. Various approaches have been proposed to address this issue. Read More

View Article and Full-Text PDF

The value of multimodal imaging with I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia.

Neurobiol Aging 2021 03 15;99:11-18. Epub 2020 Dec 15.

Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address:

Reduced nigrostriatal uptake on N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-[I]iodophenyl) nortropane (I-FP-CIT) SPECT reflects dopamine dysfunction, while other imaging markers could be complementary when used together. We assessed how well I-FP-CIT SPECT differentiates dementia with Lewy bodies (DLBs) from Alzheimer's disease dementia (ADem) and whether multimodal imaging provides additional value. I-FP-CIT SPECT, magnetic resonance imaging, [F]2-fluoro-deoxy-D-glucose-positron emission tomography (PET), and C-Pittsburgh compound B (PiB)-PET were assessed in 35 participants with DLBs and 14 participants with ADem (autopsy confirmation in 9 DLBs and 4 ADem). Read More

View Article and Full-Text PDF

Subjective sleep parameters in prodromal Alzheimer's disease: a case-control study.

Braz J Psychiatry 2020 Dec 9. Epub 2020 Dec 9.

Departamento de Neurologia, Universidade de São Paulo (USP), São Paulo, SP, Brazil.

Objective: People with Alzheimer's disease (AD) dementia have impaired sleep. However, the characteristics of sleep in the early stages of AD are not well known, and studies with the aid of biomarkers are lacking. We assessed the subjective sleep characteristics of non-demented older adults and compared their amyloid profiles. Read More

View Article and Full-Text PDF
December 2020

Association of and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.

Neurology 2021 02 1;96(5):e650-e661. Epub 2020 Dec 1.

From the Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences (R.L.J., A.V.V., O.H.L.-V., L.E., L.I., D.N.S.-M., T.M., Z.A.M., D.C.P., J.P., A.S., M.L.G.-T., H.J.R., B.L.M., G.D.R.), and Department of Radiology and Biomedical Imaging (G.D.R.), University of California, San Francisco; Department of Diagnostic Imaging (O.H.L.-V.), Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Molecular Biophysics and Integrated Bioimaging Division (S.L.B., M.J., W.J.J., G.D.R.), Lawrence Berkeley National Laboratory; and Helen Wills Neuroscience Institute (W.J.J., G.D.R.), University of California Berkeley.

Objective: To assess whether Alzheimer disease (AD) clinical presentation and relate to the burden and topography of β-amyloid (Aβ) and tau pathologies using in vivo PET imaging.

Methods: We studied 119 Aβ-positive symptomatic patients aged 48-95 years, including 29 patients with logopenic variant primary progressive aphasia (lvPPA) and 21 with posterior cortical atrophy (PCA). Pittsburgh compound B (PiB)-Aβ and flortaucipir (tau)-PET standardized uptake value ratio (SUVR) images were created. Read More

View Article and Full-Text PDF
February 2021

Association of Cerebrospinal Fluid Adiponectin Levels With Cerebral Glucose Metabolism In Mild Cognitive Impairment: A Pilot Study.

Curr Alzheimer Res 2020 ;17(12):1126-1132

Department of Neurology, Faculty of Medicine, Oita University, Oita 879-5593, Japan.

Background: Adiponectin has been implicated in the pathophysiology of dementia, especially Alzheimer's disease. However, the association between cerebrospinal fluid (CSF) adiponectin levels and positron emission tomography (PET) imaging remains unclear.

Objective: To explore whether CSF adiponectin levels are associated with C-Pittsburgh compound B (PiB) or F-fluorodeoxyglucose (FDG) uptake in amnestic mild cognitive impairment (MCI) subjects. Read More

View Article and Full-Text PDF
January 2020

Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline.

Alzheimers Dement (N Y) 2020 31;6(1):e12096. Epub 2020 Oct 31.

Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.

Importance: Adults with Down syndrome (DS) are at high-risk of revealing Alzheimer's disease (AD) pathology, in part due to the triplication of chromosome 21 encoding the amyloid precursor protein. Adults with DS are uniformly affected by AD pathology by their 30's and have a 70% to 80% chance of clinical dementia by their 60's. Our previous studies have assessed longitudinal changes in amyloid beta (Aβ) accumulation in DS. Read More

View Article and Full-Text PDF
October 2020

[C]PIB amyloid quantification: effect of reference region selection.

EJNMMI Res 2020 Oct 19;10(1):123. Epub 2020 Oct 19.

Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Background: The standard reference region (RR) for amyloid-beta (Aβ) PET studies is the cerebellar grey matter (GMCB), while alternative RRs have mostly been utilized without prior validation against the gold standard. This study compared five commonly used RRs to gold standard plasma input-based quantification using the GMCB.

Methods: Thirteen subjects from a test-retest (TRT) study and 30 from a longitudinal study were retrospectively included (total: 17 Alzheimer's disease, 13 mild cognitive impairment, 13 controls). Read More

View Article and Full-Text PDF
October 2020

Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome.

Alzheimers Dement (Amst) 2020 13;12(1):e12096. Epub 2020 Sep 13.

Waisman Center University of Wisconsin-Madison Madison Wisconsin USA.

Introduction: There is a critical need to identify measures of cognitive functioning sensitive to early Alzheimer's disease (AD) pathophysiology in Down syndrome to advance clinical trial research in this at-risk population. The objective of the study was to longitudinally track performance on cognitive measures in relation to neocortical and striatal amyloid beta (Aβ) in non-demented Down syndrome.

Methods: The study included 118 non-demented adults with Down syndrome who participated in two to five points of data collection, spanning 1. Read More

View Article and Full-Text PDF
September 2020

Effect of Feru-guard 100M on amyloid-beta deposition in individuals with mild cognitive impairment.

Psychogeriatrics 2020 Sep 6;20(5):726-736. Epub 2020 Aug 6.

Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.

Aim: Many researchers argue that Alzheimer's disease is at least partly caused by deposition of amyloid beta (Aβ) in the brain. Ferulic acid (FA) and Angelica archangelica (AA) are candidate agents for reducing Aβ and improving cognitive function. Feru-guard 100M is a supplement containing FA and AA extract. Read More

View Article and Full-Text PDF
September 2020

Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging study.

Neurology 2020 07 24;95(2):e166-e178. Epub 2020 Jun 24.

From the Departments of Neurology (A.R., E.S., I.D., H.H., S.J., H.J., A.L., H.S., S.P., R.S.I., L.M.) and Radiology (J.D., M.J.d.L., L.M.), Weill Cornell Medical College; Division of Biostatistics and Epidemiology (K.H., I.D.), Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY; ADM Diagnostics (R.A., D.M.), Chicago, IL; and Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson.

Objective: To investigate sex differences in late-onset Alzheimer disease (AD) risks by means of multimodality brain biomarkers (β-amyloid load via C-Pittsburgh compound B [PiB] PET, neurodegeneration via F-fluorodeoxyglucose [FDG] PET and structural MRI).

Methods: We examined 121 cognitively normal participants (85 women and 36 men) 40 to 65 years of age with clinical, laboratory, neuropsychological, lifestyle, MRI, FDG- and PiB-PET examinations. Several clinical (e. Read More

View Article and Full-Text PDF

Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation.

Ann Nucl Med 2020 Sep 13;34(9):629-635. Epub 2020 Jun 13.

Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Objective: Visual evaluation is the standard for amyloid positron emission tomography (PET) examination, though the result depends upon the physician's subjective review of the images. Therefore, it is expected that objective quantitative evaluation is useful for image interpretation. In this study, we examined the usefulness of the quantitative evaluation of amyloid PET using a PET-only quantification method in comparison with visual evaluation. Read More

View Article and Full-Text PDF
September 2020

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study.

J Nucl Med 2020 12 8;61(12):1814-1819. Epub 2020 May 8.

Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Department of Neurology, Tianjin Dementia Institute, Tianjin Huanhu Hospital, Tianjin, China

Cerebral β-amyloid deposits and regional glucose metabolism assessed by PET are used to distinguish between Alzheimer disease (AD) and other dementia syndromes. In the present multicenter study, we estimated the prevalence of β-amyloid deposits on PET imaging in a wide variety of dementia syndromes and mild cognitive impairment (MCI) within a memory clinic population. Of the 1,193 consecutive patients with cognitive impairment (CI) who received 1 C-PIB PET or F-AV45 PET or both C-PIB PET and F-AV45 PET, 960 were diagnosed with AD, 36 with frontotemporal dementia (FTD), 5 with dementia with Lewy bodies, 144 with MCI, 29 with vascular dementia, 4 with corticobasal syndrome, and 15 with unclassifiable dementia. Read More

View Article and Full-Text PDF
December 2020

Brain amyloid, cortical thickness, and changes in activities of daily living.

Ann Clin Transl Neurol 2020 04 21;7(4):474-485. Epub 2020 Apr 21.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

Objective: To examine the association of baseline elevated brain amyloid and neurodegeneration with changes in activities of daily living in participants without dementia (ND; i.e., cognitively unimpaired and participants with mild cognitive impairment) at baseline in the population-based Mayo Clinic Study of Aging. Read More

View Article and Full-Text PDF

TRanscranial AlterNating current Stimulation FOR patients with Mild Alzheimer's Disease (TRANSFORM-AD study): Protocol for a randomized controlled clinical trial.

Alzheimers Dement (N Y) 2020 7;6(1):e12005. Epub 2020 Apr 7.

Innovation Center for Neurological Disorders Department of Neurology, Xuanwu Hospital Capital Medical University National Clinical Research Center for Geriatric Diseases Beijing China.

Introduction: Recently, transcranial alternating current stimulation (tACS), which can interact with ongoing neuronal activity, has emerged as a potentially effective and promising treatment for Alzheimer's disease (AD), and the 40 Hz gamma frequency was suggested as a suitable stimulation frequency for AD.

Methods: The TRANSFORM-AD study is a double-blind, randomized-controlled trial that will include 40 individuals with mild AD. Eligible patients need to have amyloid β (Aβ) loads examined by Pittsburgh compound B (PiB) positron emission tomography (PET) or decreased Aβ level in cerebrospinal fluid. Read More

View Article and Full-Text PDF

The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.

Medicine (Baltimore) 2020 Apr;99(16):e19620

Department of Neurology.

For the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), variable neuroimaging and neuropsychological tests have been used. We aimed to evaluate the correlation of neuropsychological domain with new amyloid positron emission tomography (PET) study and to validate the availability of new PET tracer.We enrolled 20 patients who underwent C-PiB-PET/CT, new PET tracer F-FC119S PET/CT from November, 2014 to July, 2015. Read More

View Article and Full-Text PDF

Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning.

Inf Fusion 2020 Jun 7;58:153-167. Epub 2020 Jan 7.

Department of Signal Theory, Telematics and Communications, University of Granada, Granada (Spain).

Despite subjects with Dominantly-Inherited Alzheimer's Disease (DIAD) represent less than 1% of all Alzheimer's Disease (AD) cases, the Dominantly Inherited Alzheimer Network (DIAN) initiative constitutes a strong impact in the understanding of AD disease course with special emphasis on the presyptomatic disease phase. Until now, the 3 genes involved in DIAD pathogenesis (PSEN1, PSEN2 and APP) have been commonly merged into one group (Mutation Carriers, MC) and studied using conventional statistical analysis. Comparisons between groups using null-hypothesis testing or longitudinal regression procedures, such as the linear-mixed-effects models, have been assessed in the extant literature. Read More

View Article and Full-Text PDF

Multimodal analysis using [C]PiB-PET/MRI for functional evaluation of patients with Alzheimer's disease.

EJNMMI Res 2020 Mar 30;10(1):30. Epub 2020 Mar 30.

Department of Psychiatry, Faculty of Medical Sciences, University of Fukui, 23-3, Matsuoka-Shimaizuki, Eiheiji-cho, Fukui, 910-1193, Japan.

Background: Multimodal PET/MRI image data simultaneously obtained from patients with early-stage of Alzheimer's disease (eAD) were assessed in order to observe pathophysiologic and functional changes, as well as alterations of morphology and connectivity in the brain. Fifty-eight patients with mild cognitive impairment and early dementia (29 males, 69 ± 12 years) underwent [C]Pittsburgh compound-B (PiB) PET/MRI with 70-min PET and MRI scans. Sixteen age-matched healthy controls (CTL) (9 males, 68 ± 11 years) were also studied with the same scanning protocol. Read More

View Article and Full-Text PDF

Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly.

Neurology 2020 04 26;94(17):e1793-e1802. Epub 2020 Mar 26.

From the Departments of Neurology (D.Z.C., E.K.S.L., B.F.B., M.M.M., D.S.K., R.C.P.), Radiology (C.G.S., V.J.L., A.R., C.R.J., P.V.), and Health Sciences Research (S.A.P., M.M.M.), Mayo Clinic, Rochester, MN.

Objective: To assess whether informant-reported apneas during sleep (witnessed apneas) in cognitively unimpaired (CU) elderly persons are associated with higher levels of brain tau.

Methods: From the population-based Mayo Clinic Study of Aging, we identified 292 CU elderly ≥65 years of age with both AV-1451 tau-PET and Pittsburgh compound B (PiB)-PET scans and whose bed partners and close relatives had completed a questionnaire that assessed whether participants had witnessed apneas during sleep. For this cross-sectional analysis, we selected the entorhinal and inferior temporal cortices as our regions of interest (ROIs) because they are highly susceptible to tau accumulation. Read More

View Article and Full-Text PDF

18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.

J Alzheimers Dis 2020 ;74(2):589-601

Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.

Background: Tau positron emission tomography (PET) imaging is used in research, but its relation to cerebrospinal fluid (CSF) tau and other Alzheimer's disease (AD)-related clinical measures is unclear in mild cognitive impairment with AD biomarkers (MCI-AD).

Objective: To determine associations between 18F-flortaucipir PET and CSF AD biomarkers, cognitive functioning, and neuroimaging measures in MCI-AD.

Methods: In 29 participants 50 years or older with MCI-AD, 18F-flortaucipir PET, CSF total tau (T-tau), phosphorylated tau181p (P-tau), amyloid-β (Aβ), structural MRI, and neuropsychological testing were collected as baseline assessments of an ongoing clinical trial. Read More

View Article and Full-Text PDF
January 2020

Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.

Eur J Nucl Med Mol Imaging 2020 10 13;47(11):2666-2680. Epub 2020 Feb 13.

Laboratory of Nuclear Medicine (LIM 43), Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Purpose: [F]FDG-PET and [C]PIB-PET are validated as neurodegeneration and amyloid biomarkers of Alzheimer's disease (AD). We used a PET staging system based on the 2018 NIA-AA research framework to compare the proportion of amyloid positivity (A+) and hypometabolism ((N)+) in cases of mild probable AD, amnestic mild cognitive impairment (aMCI), and healthy controls, incorporating an additional classification of abnormal [F]FDG-PET patterns and investigating the co-occurrence of such with A+, exploring [F]FDG-PET to generate hypotheses in cases presenting with clinical-biomarker "mismatches."

Methods: Elderly individuals (N = 108) clinically classified as controls (N = 27), aMCI (N = 43) or mild probable AD (N = 38) were included. Read More

View Article and Full-Text PDF
October 2020

Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis.

J Am Coll Cardiol 2020 02;75(4):380-390

Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address:

Background: It remains unknown whether the noninvasive evaluation of the degree of amyloid deposition in the myocardium can predict the prognosis of patients with light chain (AL) cardiac amyloidosis.

Objectives: The purpose of this study was to demonstrate that C-Pittsburgh B compound positron emission tomography (C-PiB PET) is useful for prognostication of AL cardiac amyloidosis by noninvasively imaging the myocardial AL amyloid deposition.

Methods: This study consecutively enrolled 41 chemotherapy-naïve AL cardiac amyloidosis patients. Read More

View Article and Full-Text PDF
February 2020

Association of peripheral inflammatory markers with connectivity in large-scale functional brain networks of non-demented older adults.

Brain Behav Immun 2020 07 11;87:388-396. Epub 2020 Jan 11.

Division of Geriatric Medicine and Gerontology, Center on Aging and Health, Johns Hopkins University School of Medicine, Baltimore, United States. Electronic address:

Background: Systemic inflammation has emerged as a risk factor for cognitive decline and Alzheimer's disease, but inflammation's effect on distributed brain networks is unclear. We examined the relationship between peripheral inflammatory markers and subsequent functional connectivity within five large-scale cognitive networks and evaluated the modifying role of cortical amyloid and APOE ε4 status.

Methods: Blood levels of soluble tumor necrosis factor-alpha receptor-1 and interleukin 6 were assessed in 176 participants (at baseline mean age: 65 (SD 9) years; 63% women; 85% cognitively normal, 15% mild cognitive impairment (MCI)) and were combined to derive an Inflammatory Index. Read More

View Article and Full-Text PDF

White matter fiber density abnormalities in cognitively normal adults at risk for late-onset Alzheimer's disease.

J Psychiatr Res 2020 03 3;122:79-87. Epub 2020 Jan 3.

Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta, Instituto de Neurociencias FLENI-CONICET, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina; Departamento de Física, Facultad de Cs. Exactas y Naturales, Universidad de Buenos Aires, Argentina.

Tau accumulation affecting white matter tracts is an early neuropathological feature of late-onset Alzheimer's disease (LOAD). There is a need to ascertain methods for the detection of early LOAD features to help with disease prevention efforts. The microstructure of these tracts and anatomical brain connectivity can be assessed by analyzing diffusion MRI (dMRI) data. Read More

View Article and Full-Text PDF

Cerebral microbleed incidence, relationship to amyloid burden: The Mayo Clinic Study of Aging.

Neurology 2020 01 4;94(2):e190-e199. Epub 2019 Dec 4.

From the Departments of Neurology (J.G.-R., A.A.R., R.D.B., M.M.M., D.S.K., R.C.P.), Health Sciences Research (T.L., J.G., J.A., S.A.P., M.M.M., W.K.), and Radiology (A.J.S., J.H., V.J.L., C.R.J., P.V., K.K.), Mayo Clinic, Rochester, MN.

Objective: To determine the incidence of cerebral microbleeds (CMBs) and the association of amyloid PET burden with incident CMBs.

Methods: A total of 651 participants, age ≥50 years (55% male), underwent 3T MRI scans with ≥2 separate T2*-weighted gradient recalled echo sequences from October 2011 to August 2017. Eighty-seven percent underwent C Pittsburgh compound B (PiB) PET scans. Read More

View Article and Full-Text PDF
January 2020